Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
6.190
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,030
Open
6.190
Bid (Size)
5.100 (9)
Ask (Size)
5.500 (2)
Prev. Close
6.190
Today's Range
6.190 - 6.190
52wk Range
5.010 - 12.75
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates
Today 6:30 EDT
From
Compass Pathways plc
Via
Business Wire
Uncovering Potential: Compass Pathways's Earnings Preview
October 30, 2024
Via
Benzinga
Performance
YTD
-31.15%
-31.15%
1 Month
-1.75%
-1.75%
3 Month
-18.87%
-18.87%
6 Month
-27.00%
-27.00%
1 Year
+8.03%
+8.03%
More News
Read More
12 Health Care Stocks Moving In Friday's After-Market Session
October 25, 2024
Via
Benzinga
Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024
October 24, 2024
From
Compass Pathways plc
Via
Business Wire
Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes
October 07, 2024
Via
Benzinga
Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder
September 26, 2024
Via
Benzinga
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
September 23, 2024
From
Compass Pathfinder Limited
Via
Business Wire
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
September 15, 2024
Via
Talk Markets
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
September 12, 2024
Via
Benzinga
Exposures
Product Safety
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
September 10, 2024
Via
Talk Markets
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
September 06, 2024
Via
Talk Markets
Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down
September 05, 2024
Via
Benzinga
Exposures
Product Safety
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
September 05, 2024
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
August 26, 2024
Via
Benzinga
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
August 24, 2024
Via
Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
August 15, 2024
Via
Talk Markets
Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript
August 01, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
July 31, 2024
Via
Benzinga
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
July 14, 2024
Via
Talk Markets
3 Dirt-Cheap Drug Developers With Blockbuster Potential
July 11, 2024
Via
InvestorPlace
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
July 08, 2024
Via
InvestorPlace
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
July 02, 2024
Via
InvestorPlace
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
June 22, 2024
Via
Talk Markets
Should You Buy the Dip on Compass Pathways Stock?
June 12, 2024
Via
The Motley Fool
Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know.
June 10, 2024
Via
The Motley Fool
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.